Bortezomib: all 701 studies that test it

Page 3 of 8. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.

• The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft CandidatesCompletedNCT00722722Phase 2Results posted
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00722137Phase 3Results posted
• Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00719901Phase 1/2Results posted
• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney FunctionTerminatedNCT00718640Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Preemptive Strike With Bortezomib in Multiple Myeloma PatientsTerminatedNCT00657553Phase 3Results posted
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaActive, not recruitingNCT00644228Phase 3Results posted
• A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular LymphomaCompletedNCT00636792Phase 2Results posted
• A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)CompletedNCT00608907Phase 1Results posted
• Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and NeckCompletedNCT00581360Phase 2Results posted
• Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast CancerTerminatedNCT00574236Phase 2Results posted
• UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideTerminatedNCT00574080Phase 3Results posted
• VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell LymphomaCompletedNCT00571493Phase 1/2Results posted
• UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicableResults posted
• Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
• An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell TransplantationTerminatedNCT00548717Phase 2Results posted
• Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's LymphomaCompletedNCT00547534Phase 2Results posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple MyelomaCompletedNCT00523848Phase 2Results posted
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition DiseaseCompletedNCT00520767Phase 2Results posted
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaTerminatedNCT00510887Phase 2Results posted
• Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCLCompletedNCT00504751Phase 2Results posted
• Bortezomib and Rituximab for Patients With Waldenstrom's MacroglobulinemiaActive, not recruitingNCT00492050Phase 2Results posted
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
• A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaTerminatedNCT00479167Phase 2Results posted
• Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
• Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
• A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00464178Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaTerminatedNCT00441168Phase 2Results posted
• Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00440726Phase 1/2Results posted
• Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell TransplantCompletedNCT00439556Phase 2Results posted
• Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)CompletedNCT00426855Phase 1/2Results posted
• Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00425750Phase 2Results posted
• PS-341 Followed by Removal of Prostate for Those With Prostate CancerCompletedNCT00425503Phase 2Results posted
• Phase I/II Study to Evaluate the Efficacy and Safety of a Combination ChemotherapyTerminatedNCT00424840Phase 1Results posted
• Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)CompletedNCT00422799Phase 2Results posted
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic CancerTerminatedNCT00416793Phase 2Results posted
• VELCADE,Rituximab,Cyclophosphamide and DecadronTerminatedNCT00413959Phase 2Results posted
• Study of VELCADE® With Mitoxantrone and Etoposide for LeukemiasCompletedNCT00410423Phase 1/2Results posted
• Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host DiseaseCompletedNCT00408928Phase 2Results posted
• Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsCompletedNCT00389805Phase 1/2Results posted
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyCompletedNCT00381940Phase 2Results posted
• Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCLCompletedNCT00379574Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT00378209Phase 2Results posted
• Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00378105Phase 1/2Results posted
• S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00376961Phase 2Results posted
• Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular LymphomaTerminatedNCT00372905Phase 1/2Results posted
• Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHLCompletedNCT00369707Phase 2Results posted
• Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
• Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple MyelomaTerminatedNCT00366106Phase 2Results posted
• Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerCompletedNCT00362882Phase 2Results posted
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's LymphomaCompletedNCT00312845Phase 3Results posted
• Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell LymphomaCompletedNCT00310037Phase 2Results posted
• Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell TransplantsCompletedNCT00307086Phase 2Results posted
• Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-AmyloidosisCompletedNCT00298766Phase 1/2Results posted
• Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT00295932Phase 1/2Results posted
• A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's LymphomaTerminatedNCT00290706Phase 1/2Results posted
• Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple MyelomaCompletedNCT00287872Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Kidney CancerCompletedNCT00276614Phase 2Results posted
• Bortezomib in Treating Patients With Myelodysplastic SyndromesCompletedNCT00262873Phase 2Results posted
• Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's LymphomaCompletedNCT00262860Phase 2Results posted
• MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationTerminatedNCT00256776Phase 3Results posted
• Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms MacroglobulinemiaCompletedNCT00250926Phase 2Results posted
• Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's LymphomaCompletedNCT00201877Phase 2Results posted
• Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate CancerTerminatedNCT00183937Phase 2Results posted
• Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaCompletedNCT00182637Phase 2Results posted
• Bortezomib (Velcade) in Patients With Untreated Multiple MyelomaCompletedNCT00153920Phase 2Results posted
• Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHLCompletedNCT00151320Phase 1/2Results posted
• Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple MyelomaCompletedNCT00148317Phase 2Results posted
• Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00128921Phase 2Results posted
• S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00124579Phase 2Results posted
• Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerCompletedNCT00118144Phase 2Results posted
• EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell LymphomaCompletedNCT00114738Phase 2Results posted
• Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))CompletedNCT00111813Phase 1Results posted
• Tamoxifen and Bortezomib to Treat Recurrent Brain TumorsCompletedNCT00108069Phase 2Results posted
• Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine TherapyCompletedNCT00104871Phase 2Results posted
• Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerCompletedNCT00093756Phase 1/2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple MyelomaCompletedNCT00084747Phase 1/2Results posted
• Doxorubicin and Bortezomib in Treating Patients With Liver CancerCompletedNCT00083226Phase 2Results posted
• Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00075881Phase 2Results posted
• Bortezomib in Treating Patients With Lymphoproliferative DisordersCompletedNCT00023764Phase 2Results posted
• Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal CancerCompletedNCT00023712Phase 2Results posted
• Feasibility of Using Bortezomib with or Without Chemotherapy in Patients with Atypical Teratoid/rhabdoid TumorsActive, not recruitingNCT06853080Phase 2
• Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell TransplantationWithdrawnNCT06348147Phase 2
• An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid ArthritisActive, not recruitingNCT06215638Not applicable
• Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Phase 3
• Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN DeletionActive, not recruitingNCT06029998Phase 2
• Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for HypophosphatasiaWithdrawnNCT06015750Phase 4
• SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Phase 2
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHDWithdrawnNCT05895201Phase 1/2

← Bortezomib overview